The stock is on the nasdaq top gainers list today on Acquisition news, currently trading at 9.3, up 6.49, gaining 226.92% on volume of over 28 Million shares as of this report.

Praxis Precision (PRAX) Medicines announced that that it will present preclinical and clinical data from three of its epilepsy programs at the American Epilepsy Society, AES, Annual Meeting, being ...

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Gain Therapeutics (GANX – Research Report), retaining the price target of ...

Dundee University spin-out Exscientia has been taken over by US pharmaceutical rival Recursion, in a deal worth around £500m. The firm was delisted from the NASDAQ stock exchange on Wednesday after ...

Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, ...

Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.

The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of ...

a preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R, according to a release. Traders […] "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor ...

Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause ...

Incyte (INCY) shares halted after speculation of takeover bid from Merck (MRK) per Sky News report by Mark Kleinman.

While the S&P/ASX 200 Health Care index (ASX:XHJ) was down 1.4% for the past five days, Neuren has soared on positive news.

It's a bad day to be an electric-vehicle investor. That is, unless, you own Tesla stock. Shares in Elon Musk's EV company jumped 15% Wednesday, bucking a wider industry selloff. The move reflects ...